Cover Image
市場調查報告書

代謝異常的肽治療藥:2016-2025年

Peptide Therapeutics in Metabolic Disorders, 2016 - 2025

出版商 ROOTS ANALYSIS 商品編碼 352420
出版日期 內容資訊 英文 436 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
代謝異常的肽治療藥:2016-2025年 Peptide Therapeutics in Metabolic Disorders, 2016 - 2025
出版日期: 2016年02月08日 內容資訊: 英文 436 Pages
簡介

本報告提供代謝異常的肽治療藥市場現況與展望的相關調查,與成為開發中產品的開發階段,給藥途徑,及標的每代謝疾病的市場分析提供,創新的技術平台遞送(給藥)系統,主要的代謝疾病的流行病學、患者統計,及治療藥的今後的銷售額預測等彙整資料,為您概述為以下內容。

第1章 序章

第2章 摘要整理

第3章 肽治療的簡介

  • 本章概要
  • 肽:簡介
  • 肽:
  • 肽治療藥:簡介
  • 肽治療藥:分類
  • 肽治療藥:製造方法
  • 肽治療藥的優點
  • 肽治療藥的缺點
  • 肽治療藥主要的物理化學特性的變化

第4章 代謝疾病的簡介

  • 本章概要
  • 代謝疾病:簡介
  • 代謝疾病:分類
  • 代謝疾病:最有前途的疾病

第5章 代謝疾病的肽治療藥:目前的市場情勢

  • 本章概要
  • 肽治療藥:整體市場概要
  • 肽治療藥:代謝疾病狀況
    • 認證藥
    • 臨床實驗平台
    • 前臨床/藥物研發開發平台
    • 後期開發各階段
    • 各適應症
    • 各給藥途徑
    • 各類比類型
    • 各肽類型
    • 各投藥頻率
  • 肽治療市場:代謝疾病
    • 預測手法、範圍
    • 整體市場規模、預測

第6章 糖尿病的肽治療藥

  • 本章概要
  • 糖尿病:流行病學
  • 目前市場情況
  • 開發平台分析
  • 後期開發各階段
  • 各次症狀
  • 各類比類型
  • 各給藥途徑
  • 各投藥頻率
  • 各肽類型
  • Lyxumia / Lixisenatide (Sanofi)
  • BYDUREON / Exenatide Once Weekly / Exenatide Extended Release (AstraZeneca)
  • Semaglutide / NN9535 / NN9924 / OG217SC (Novo Nordisk)
  • ITCA 650 (Intarcia Therapeutics / Servier)
  • Polyethylene Glycol Loxenatide / PEX 168 (Jiangsu Hansoh Pharmaceutical Co.) 、其他

第7章 肢端肥大症的肽治療藥

  • 本章概要
  • 肢端肥大症:流行病學
  • 目前市場情況
  • 開發平台分析
  • 後期開發各階段
  • 各給藥途徑
  • 各投藥頻率
  • 各肽類型
  • Signifor LAR / Pasireotide (Novartis)
  • Mycapssa / Octreolin / Oral Octreotide (Chiasma Pharma)
  • Somatoprim / DG3173 / COR-005 (Aspireo Pharmaceuticals / Cortendo AB)
  • ITF 2984 (Italfarmaco)
  • CAM2029 (Camurus Pharmaceuticals / Novartis)
  • 肽治療藥市場:肢端肥大症

第8章 肥胖的肽治療藥

  • 本章概要
  • 肥胖:流行病學
  • 目前市場情況
  • 開發平台分析
  • 後期開發各階段
  • 各標的次症狀
  • 各類比類型
  • 各給藥途徑
  • 各投藥頻率
  • Saxenda / Liraglutide 3 mg (Novo Nordisk)
  • Setmelanotide / RM-493 / BIM-22493 (Rhythm Pharmaceuticals)
  • LY2944876 / TT-401 (Eli Lilly / Transition Therapeutics)
  • 肽治療藥市場:肥胖

第9章 骨質疏鬆症的肽治療藥

  • 本章概要
  • 骨質疏鬆症:流行病學
  • 目前市場情況
  • 開發平台分析
  • 各後期開發階段
  • 各類比類型
  • 各給藥途徑
  • 各投藥頻率
  • 各肽類型
  • TBRIA (Tarsa Therapeutics / Unigene Laboratories)
  • Abaloparatide / BIM44058 / BA058 (Radius Health / TEIJIN FIBERS製藥)
  • 肽治療藥市場:骨質疏鬆症

第10章 其他代謝疾病的肽治療藥

  • 本章概要
  • 目前市場情況
  • 開發平台分析
  • 各後期開發階段
  • 各類比類型
  • 各給藥途徑
  • 各投藥頻率
  • SCENESSE / Afamelanotide / CUV1647 (Clinuvel Pharmaceuticals)
  • Signifor / Pasireotide (Novartis)
  • AEM-28 (LipimetiX Development)
  • BMN-111 / Vosoritide (BioMarin Pharmaceutical)
  • AZP-131 (Alize Pharma)
  • 肽治療藥市場:其他代謝疾病

第11章 主要技術平台

  • 本章概要
  • ArisCrown Technology (ArisGen)
  • Chimeric Apo E Mimetic Peptide (CHAMP) Technology (LipimetiX Development)
  • Glide SDI (Solid Dose Injector) (Glide Technologies)
  • FluidCrystal Injection Depot (Camurus Pharmaceuticals)
  • PC-DAC (ConjuChem)
  • PharmFilm Technology Platform (MonoSol Rx)
  • Intarcia Technology Platform (Intarcia Therapeutics)
  • Eligen Technology (Emisphere Technologies)
  • XTEN Technology (Amunix)
  • Axcess Oral Drug Delivery Technology (Proxima Concepts / Diabetology)
  • POD (Protein Oral Delivery) Technology (Oramed Pharmaceuticals)
  • Transient Permeability Enhancer (TPE) Technology (Chiasma)
  • SmartDepot (Peptron)
  • 3M Microneedle Drug Delivery Technology (3M Drug Delivery Systems)
  • Gastrointestinal Permeation Enhancement Technology (GIPET) (Merrion Pharmaceuticals)
  • LAPSCOVERY Technology (Hanmi Pharmaceuticals)
  • Peptelligence Technology (Unigene Laboratories / Enteris Biopharma)

第12章 專家的採訪

第13章 結論

第14章 附錄1:表格資料

第15章 附錄2:企業、組織清單

圖表

目錄
Product Code: RA10054

Peptide therapeutics, due to their numerous advantages such as high selectivity, stability, efficacy, safety, bioavailability and tolerability offer a number of benefits over other therapeutic classes. In addition, peptides (when compared to proteins) are much smaller in size and can be easily synthesized, optimized and evaluated as viable therapeutic solutions for a number of diseases. These highly favourable and intrinsic characteristics of peptides have caused an evident shift in the interest of pharmaceutical / life science companies towards developing peptide based drugs during the last decade. The number of marketing approvals granted to such molecules has increased recently. Researchers have continued to develop novel strategies to synthesize customized peptides to elicit desired biological responses.

Metabolic disorders have gained significant attention for the development of peptide based therapies.Some of the marketed drugs in this space, including BYETTA® / BYDUREON® and Victoza®, have already emerged as blockbusters with over USD 1 billion annual sales. It is worth highlighting that the evolution of peptides into potent therapeutic solutions has been facilitated by a variety of novel technologies that have been developed by drug / technology developers. Technologies designed to enhance the stability, increase the bioavailability and facilitate the effective delivery of peptides have acted as key enablers to the market's growth. Specifically, technologies that offer alternative routes of administration (oral / intranasal / transdermal) and sustained drug delivery over a longer time duration are expected to significantly improve patient compliance. In fact, companies have actively entered into collaboration with other stakeholders to either acquire or develop peptide therapies. There have also been a growing number of partnerships related to technology licensing.

Synopsis:

The “Peptide Therapeutics in Metabolic Disorders, 2016-2025” report provides a comprehensive analysis of the current market landscape and future outlook of peptide therapeutics targeting metabolic disorders. Novartis' Miacalcin, a calcitonin analogue, was the first peptide therapeutic approved for the treatment of post-menopausal osteoporosis in 1986. Following Miacalcin, several more peptide based therapies targeting various metabolic diseases have been approved so far. The overall pipeline is rich and continues to grow at a healthy pace. These therapies hold the potential to capture a significant share of the pharmaceutical market in the foreseen future.

A majority of peptide therapeutics that we identified during our research are being developed for the treatment of diabetes, obesity, osteoporosis and acromegaly. In addition, there are several peptide therapeutics targeting other metabolic disorders such as Cushing's disease, hypoglycemia, cystic fibrosis and achondroplasia.

One of the key objectives of the study is to review and quantify the opportunities laid by the development programs of both small and big pharma firms. Amongst other elements, the report elaborates on the following key areas:

  • The current state of the market with respect to key players, developmental stage of pipeline products (both clinical / pre-clinical), route of administration and metabolic indications being targeted.
  • The innovative technology platforms and delivery systems being offered to eliminate the challenges associated with the administration of peptide therapeutics.
  • Partnerships that have taken place in the recent past covering research and development collaborations, manufacturing agreements, license agreements specific to technology platforms or product, co-development and co-commercialization of promising candidates.
  • Recently approved and mid / late stage peptide therapeutics in terms of their history of development, available formulations, associated patents, key clinical trials and results.
  • The epidemiology and patient population for each key metabolic indication.

The report provides sales forecast for the overall peptide therapeutics market targeting metabolic disorders for the period 2016 - 2025. We have provided three market forecast scenarios to add robustness to our model. Accordingly, the conservative, base and optimistic scenarios represent three different tracks of industry evolution. For the purposes of the study, we interviewed important stakeholders to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. All actual figures have been sourced and analyzed from publicly available information.

Example Highlights:

  • 1. During our research, we identified over 20 approved formulations of peptide therapeutics for various metabolic disorders. The pipeline is rich with several molecules in clinical / preclinical / discovery stage. In our research, we came across ~90 peptide based drugs that are currently under development; a significant proportion (~50%) is in early stages of development.
  • 2. GLP-1 analogues, with 35% share, are the most common. This is followed by somatostatin analogues (14%), PTH analogues (7%), glucagon analogues (5%) and calcitonin analogues (4%). Companies are also developing novel peptide analogues such as Apolipoprotein E mimetic peptide analogues, angiotensin (1-7) analogues, unacylated ghrelin analogues, C-type natriuretic peptide analogues, oxyntomodulin analogues, Human proIslet peptide analogues, Glucose-Dependent Insulinotropic peptide analogues, melanocortin receptor analogues and vasoactive intestinal peptide analogues.
  • 3. Diabetes, obesity, osteoporosis and acromegaly have gained significant traction so far; peptide therapeutics being developed for these indications are likely to be the primary revenue drivers in near future. In addition, peptide based drugs are also being evaluated as treatment solutions for other metabolic disorders such as erythropoietic protoporphyria, lipodystrophy-HIV related, homozygous familial hypercholesterolemia, achondroplasia, Cushing's disease, hypercalcemia and growth hormone deficiency.
  • 4. Discovery and implementation of novel technologies to enhance specific properties such as stability, half-life and bioavailability have led the research efforts. Technologies such as ArisGen's ArisCrown technology, Biolaxy's NOD technology, Chiasma's TPE® technology, Emisphere's Eligen® formulation technology, Merrion's GIPET®, Oramed's POD™ technology, Proxima's Axcess™ technology and Unigene/Enteris' Peptelligence™ technology provide oral peptide delivery. Technologies such as Zosano's ZP transdermal microneedle patch systemand 3M's microneedle drug delivery technologyoffer transdermal delivery of peptides. Sustained / extended delivery of peptides is being made possible through the biodegradable polymer implant technology (SurModics), ELP platform technology (PhaseBio Pharmaceuticals), FluidCrystal® injection depot technology (Camurus Pharmaceuticals), Intarcia Platform Technology (Intarcia Therapeutics), LAPSCOVERY™ platform technology (Hanmi Pharmaceuticals), Medisorb® microsphere technology (Alkermes), SIF platform technology (Foresee Pharmaceuticals) and SmartDepot™ technology (Peptron).
  • 5. Pharmaceutical giants including Novo Nordisk, Novartis, Elli Lilly, AstraZeneca and Sanofi dominate this market while other companies such as Intarcia Therapeutics, Chiasma, Zealand Pharma and Radius Health are actively trying to gain a foothold. Several start-ups / small companies such as Amunix, APEPTICO, Apitope, ArisGen, Calista Therapeutics, Clinuvel, ConjuChem Biotechnologies, CureDM, LipimetiX Development, Longevity Biotech, Oramed Pharmaceuticals, Palatin Technologies, Rani Therapeutics, Tarsa Therapeutics and Zosano Pharma are also emerging and have one or multiple peptides in early stages of development.
  • 6. Overall, we expect the peptide therapeutics market for metabolic disorders to witness a steady growth rate over the coming decade and be worth over USD 10 billion by 2025. As expected, diabetes will account for a majority share. Ongoing technological developments and research in other metabolic disorders will fuel growth in the long term.

Research Methodology:

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information

Chapter Outlines:

Chapter 2 presents an executive summary of the report. It offers a high level view on the current scenario of the peptide therapeutics market for metabolic disorders and where it is headed in the mid-long term.

Chapter 3 provides a general introduction to peptide therapeutics. In this section, we have discussed the structure, chemistry and other fundamental aspects of peptides. In addition, we have also discussed the methods of synthesis, purification strategies and stabilization methods for peptides, along with relevant advantages and disadvantages.

Chapter 4 provides a general introduction to metabolic disorders. It includes a comprehensive classification of the various types of metabolic disorders and detailed description of the most common metabolic disorders, along with their respective causes and symptoms.

Chapter 5 provides a comprehensive overview on the landscape of peptide therapeutics for metabolic disorders. It includes information on over 80 different peptide therapeutics that are currently in various stages of development (both clinical and preclinical / discovery). It also contains a detailed analysis of the development pipeline highlighting the different types of peptides and peptide analogues used, their targeted metabolic indications, the current phase of development of each molecule, various routes of administration and the dosage frequency of drugs. In addition, we have presented a detailed ten year forecast, based on primary and secondary research, for the overall market of peptide therapeutics in metabolic disorders.

Chapter 6 focuses on peptide therapeutics that have been / are being developed to specifically target diabetes. It presents an overview of the current market scenario and provides our likely future growth outlook. It includes detailed drug profiles of marketed drugs and drugs in late stages of development. The profiles cover information on several aspects of these therapeutics such as their history of development, clinical trial results, manufacturing, product costs and related collaborations.

Chapter 7 focuses on peptide therapeutics that have been / are being developed to specifically target acromegaly. It presents an overview of the current market scenario and provides our likely future growth outlook. Similar to the previous chapter, this chapter also includes detailed drug profiles of marketed drugs and drugs in late stage of development covering information on several aspects such as their history of development, clinical trial results, manufacturing, product costs and related collaborations.

Chapter 8 focuses on peptide therapeutics that have been / are being developed to specifically target obesity. It presents an overview of the current market scenario and provides our likely future growth outlook. Similar to the earlier chapters, this chapter also includes detailed drug profiles of marketed drugs and drugs in late stage of development covering information on several aspects such as their history of development, clinical trial results, manufacturing, product costs and related collaborations.

Chapter 9 focuses on peptide therapeutics that have been / are being developed to specifically target osteoporosis. It presents an overview of the current market scenario and provides our likely future growth outlook. Similar to the earlier chapters, this chapter also includes detailed drug profiles of marketed drugs and drugs in late stage of development covering information on several aspects such as their history of development, clinical trial results, manufacturing, product costs and related collaborations.

Chapter 10 focuses on peptide therapeutics that have been / are being developed for metabolic disorders other than diabetes, obesity, osteoporosis and acromegaly. Similar to the earlier chapters, this chapter also includes detailed drug profiles of marketed drugs and drugs in late stage of development covering information on several aspects such as their history of development, clinical trial results, manufacturing, product costs and related collaborations.

Chapter 11 highlights the various technologies that are currently being utilized for the development of peptide therapeutics. It includes detailed profiles of the relatively more popular technologies covering their key features and advantages.

Chapter 12 is a collection of interview transcripts of the discussions that we held with key stakeholders in this market. These include Andrew Mallon(CEO, Calista Therapeutics), Andrew Parker (CEO, ArisGen), John Dodd (VP Discovery and Research, Palatin Technologies) and Dennis Goldberg (President, LipimetiX Development).

Chapter 13 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and also present our independent opinion based on the research and analysis described in the previous chapters.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which provides the list of companies and organizations that have been mentioned in the report.

Table of Contents

1. Preface

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. Executive Summary

3. Introduction to Peptide Therapeutics

  • 3.1. Chapter Overview
  • 3.2. Peptides: An Introduction
  • 3.3. Peptides: Structure and the Peptide Bond
  • 3.4. Peptide Therapeutics: An Introduction
  • 3.5. Peptide Therapeutics: Classification
    • 3.5.1. Synthetic Peptide Therapeutics
    • 3.5.2. Recombinant Peptide Therapeutics
  • 3.6. Peptide Therapeutics: Methods of Production
    • 3.6.1. Chemical Synthesis
      • 3.6.1.1. Solution / Liquid Phase Peptide Synthesis (LPPS)
      • 3.6.1.2. Solid Phase Peptide Synthesis (SPPS)
        • 3.6.1.2.1. Advantages of SPPS
      • 3.6.1.3. Combination of SPPS and LPPS
    • 3.6.2. Recombinant Production
    • 3.6.3 Purification of Peptide Based Therapeutics
    • 3.6.4. Peptide Therapeutics Manufacturing: Role of CMOs
  • 3.7. Advantages of Peptide Therapeutics
  • 3.8. Disadvantages of Peptide Therapeutics
  • 3.9. Alteration of Key Physico-chemical Properties of Peptide Therapeutics
    • 3.9.1. Plasma Half-Life Extension of Peptide Therapeutics: Approaches
      • 3.9.1.1. Reduction in Enzymatic Degradation of the Peptide
      • 3.9.1.2. Protection Against Enzymatic Cleavage
      • 3.9.1.3. Binding to Albumin Protein
      • 3.9.1.4. Addition of Polyethylene Glycol (PEG) Groups

4. Introduction to Metabolic Disorders

  • 4.1. Chapter Overview
  • 4.2. Metabolic Disorders: An Introduction
  • 4.3. Metabolic Disorders: Classification
    • 4.3.1. Mitochondrial Disorders
    • 4.3.2. Amino Acid Metabolism Disorders
    • 4.3.3. Porphyrias
    • 4.3.4. Lysosomal Storage Disorders
    • 4.3.5. Lipid Metabolism Disorders
    • 4.3.6. Peroxisomal Disorders
    • 4.3.7. Purine and Pyrimidine Disorders
    • 4.3.8. Carbohydrate Metabolism Disorders
  • 4.4. Metabolic Disorders: Most Prominent Diseases

5. Peptide Therapeutics in Metabolic Disorders: Current Market Landscape

  • 5.1. Chapter Overview
  • 5.2. Peptide Therapeutics: Overall Market Overview
  • 5.3. Peptide Therapeutics: Landscape of Metabolic Disorders
    • 5.3.1. Peptide Therapeutics in Metabolic Disorders: Approved Drugs
    • 5.3.2. Peptide Therapeutics in Metabolic Disorders: Clinical Pipeline
    • 5.3.3. Peptide Therapeutics in Metabolic Disorders: Pre-Clinical / Discovery Pipeline
    • 5.3.4. Peptide Therapeutics in Metabolic Disorders: Distribution by Highest Phase of Development
    • 5.3.5. Peptide Therapeutics in Metabolic Disorders: Distribution by Indication
    • 5.3.6. Peptide Therapeutics in Metabolic Disorders: Distribution by Route of Administration
    • 5.3.7. Peptide Therapeutics in Metabolic Disorders: Distribution by Type of Analogue
    • 5.3.8. Peptide Therapeutics in Metabolic Disorders: Distribution by Type of Peptide
    • 5.3.9. Peptide Therapeutics in Metabolic Disorders: Distribution by Dosage Frequency
  • 5.4. Peptide Therapeutics Market: Metabolic Disorders, 2015 - 2025
    • 5.4.1. Scope and Forecast Methodology
    • 5.4.2. Overall Market Size and Forecast

6. Peptide Therapeutics in Diabetes

  • 6.1. Chapter Overview
  • 6.2. Diabetes: Epidemiology
  • 6.3. Peptide Therapeutics in Diabetes: Current Market Landscape
  • 6.4. Peptide Therapeutics in Diabetes: Pipeline Analysis
  • 6.5. Peptide Therapeutics in Diabetes: Distribution by Highest Phase of Development
  • 6.6. Peptide Therapeutics in Diabetes: Distribution by Sub-Indication
  • 6.7. Peptide Therapeutics in Diabetes: Distribution by Type of Analogue
  • 6.8. Peptide Therapeutics in Diabetes: Distribution by Route of Administration
  • 6.9. Peptide Therapeutics in Diabetes: Distribution by Dosage Frequency
  • 6.10. Peptide Therapeutics in Diabetes: Distribution by Type of Peptide
  • 6.11. Lyxumia® / Lixisenatide (Sanofi)
    • 6.11.1. Product Overview
    • 6.11.2. Mechanism of Action
    • 6.11.3. History of Development
    • 6.11.4. Dosage Form and Regimen
      • 6.11.4.1. Lyxumia® as Combination Treatment
    • 6.11.5. Treatment Cost
    • 6.11.6. Historical Sales
    • 6.11.7. Current Status of Development
    • 6.11.8. GetGoal Phase III Clinical Trial Program
    • 6.11.9. Key Clinical Trial Results
      • 6.11.9.1. GetGoal-L-Asia: Phase III Results
      • 6.11.9.2. GetGoal-X: Phase III Results
      • 6.11.9.3. GetGoal-F1: Phase III Results
      • 6.11.9.4. Get-Goal Duo 1: Phase III Results
      • 6.11.9.5. GetGoal-P: Phase III Results
      • 6.11.9.6. ELIXA: Phase III Results
      • 6.11.9.7. GetGoal Duo-2: Phase III Results
    • 6.11.10. Collaborations
      • 6.11.10.1. License Agreement between Zealand Pharma and Sanofi
  • 6.12. BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release (AstraZeneca)
    • 6.12.1. Product Overview
    • 6.12.2. History of Development
    • 6.12.3. Mechanism of Action
    • 6.12.4. The Medisorb® Microsphere Technology
    • 6.12.5. Patents
    • 6.12.6. Dosage Form, Regimen and Price
    • 6.12.7. Historical Sales
    • 6.12.8. Current Status of Development
    • 6.12.9. DURATION Phase III Clinical Trial Program
    • 6.12.10. Key Clinical Trial Results
      • 6.12.10.1. DURATION-1: Phase III Results
      • 6.12.10.2. DURATION-2: Phase III Results
      • 6.12.10.3. DURATION-3: Phase III Results
      • 6.12.10.4. DURATION-4: Phase III Results
      • 6.12.10.5. DURATION-5: Phase III Results
      • 6.12.10.6. DURATION-6: Phase III Results
      • 6.12.10.7. DURATION-NEO-1: Phase III Results
    • 6.12.11. Collaborations
      • 6.12.11.1. Acquisition Agreement with Astra Zeneca
      • 6.12.11.2. Acquisition Agreement with BMS
      • 6.12.11.3. Product Supply Agreement with Eli Lilly
  • 6.13. Semaglutide / NN9535 / NN9924 / OG217SC (Novo Nordisk)
    • 6.13.1. Product Overview
    • 6.13.2. Mechanism of Action
    • 6.13.3. History of Development
    • 6.13.4. NN9924 (OG217SC) and the Eligen® Technology
    • 6.13.5. Manufacturing
    • 6.13.6. Dosage Form and Regimen
    • 6.13.7. Current Status of Development
      • 6.13.7.1. PIONEER Clinical Program
      • 6.13.7.2. SUSTAIN Clinical Program
    • 6.13.8. Key Clinical Trial Results
      • 6.13.8.1. NN9535: Phase III Results
      • 6.13.8.2. NN9924/OG217SC: Phase II Results
    • 6.13.9. Collaborations
      • 6.13.9.1. License Agreement with Zosano Pharma
      • 6.13.9.2. Development and Licence Agreement with Emisphere Technologies
  • 6.14. ITCA 650 (Intarcia Therapeutics / Servier)
    • 6.14.1. Product Overview
    • 6.14.2. Mechanism of Action
    • 6.14.3. History of Development
    • 6.14.4. Intarcia's Technology Platform
    • 6.14.5. Current Status of Development
    • 6.14.6. Key Clinical Trial Results
      • 6.14.6.1. FREEDOM 1 HBL: Interim Results
      • 6.14.6.2. FREEDOM-1 and FREEDOM-1 High Baseline (HBL): Top- Line Results
      • 6.14.6.3. Freedom-2 Comparative Trial: Top-Line Results
    • 6.14.7. Funding
    • 6.14.8. Collaborations
      • 6.14.8.1. Acquisition of Phoundry Pharmaceuticals
      • 6.14.8.2. Development Agreement with Numab
      • 6.14.8.3. Development and Commercialization Agreement with Servier
      • 6.14.8.4. Clinical Development Agreement with Quintiles
  • 6.15. Polyethylene Glycol Loxenatide / PEX 168 (Jiangsu Hansoh Pharmaceutical Co.)
    • 6.15.1. Product Overview
    • 6.15.2. Mechanism of Action
    • 6.15.3. Current Status of Development
    • 6.15.4. Key Clinical Trial Results
  • 6.16. Peptide p277/AVE-0277/DiaPep277 (Hyperion Therapeutics / Yeda Research and Development Company)
    • 6.16.1. Product Overview
    • 6.16.2. Mechanism of Action
    • 6.16.3. History of Development
    • 6.16.4. Current Status of Development
    • 6.16.5. Key Clinical Trial Results
      • 6.16.5.1. Phase III DIA-AID 1 Results
      • 6.16.5.2. Phase III DIA-AID 1 Extension Study Results
    • 6.16.6. Collaborations
      • 6.16.6.1. Acquisition of Horizon Pharma by Hyperion Therapeutics
      • 6.16.6.2. Acquisition of Andromeda by Hyperion Therapeutics
      • 6.16.6.3. Acquisition Agreement between Teva and Andromeda
      • 6.16.6.4. Acquisition of DeveloGen by Evotec
  • 6.17. Efpeglenatide / HM11260C (Hanmi Pharmaceuticals)
    • 6.17.1. Product Overview
    • 6.17.2. Mechanism of Action
    • 6.17.3. History of Development
    • 6.17.4. The LAPSCOVERY™ Technology
    • 6.17.5. Current Status of Development
    • 6.17.6. Key Clinical Trial Results
      • 6.17.6.1. Phase Ib Results: Type II Diabetes
      • 6.17.6.2. Phase II Results (20-week): Non-diabetic Obesity
      • 6.17.6.3. Phase II Results (12-week): Type II Diabetes
    • 6.17.7. Collaborations
      • 6.17.7.1. Product Development Agreement with Sanofi
      • 6.17.7.2. Services Agreement with Ypsomed Group
  • 6.18. PB1023 (PhaseBio Pharmaceuticals)
  • 6.19. RO6811135 (Roche)
  • 6.20. CJC-1134-PC / Albenatide (ConjuChem)
  • 6.21. Peptide Therapeutics Market: Diabetes, 2015 - 2025

7. Peptide Therapeutics in Acromegaly

  • 7.1. Chapter Overview
  • 7.2. Acromegaly: Epidemiology
  • 7.3. Peptide Therapeutics in Acromegaly: Current Market Landscape
  • 7.4. Peptide Therapeutics in Acromegaly: Pipeline Analysis
  • 7.5. Peptide Therapeutics in Acromegaly: Distribution by Highest Phase of Development
  • 7.6. Peptide Therapeutics in Acromegaly: Distribution by Route of Administration
  • 7.7. Peptide Therapeutics in Acromegaly: Distribution by Dosage Frequency
  • 7.8. Peptide Therapeutics in Acromegaly: Distribution by Type of Peptide
  • 7.9. Signifor® LAR / Pasireotide (Novartis)
    • 7.9.1. Product Overview
    • 7.9.2. History of Development
    • 7.9.3. Mechanism of Action
    • 7.9.4. Dosage Form and Regimen
    • 7.9.5. Patents
    • 7.9.6. Current Status of Development
    • 7.9.7. Key Clinical Trial Results
      • 7.9.7.1. C2305: Phase III results
      • 7.9.7.2. C2402: Phase III Results
  • 7.10. Mycapssa™ / Octreolin™ / Oral Octreotide (Chiasma Pharma)
    • 7.10.1. Product Overview
    • 7.10.2. Mechanism of Action
    • 7.10.3. History of Development
    • 7.10.4. Funding
    • 7.10.5. Transient Permeability Enhancer (TPE) Technology
    • 7.10.6. Current Status of Development
    • 7.10.7. Key Clinical Trial Results
    • 7.10.8. Collaborations
      • 7.10.8.1. Manufacturing Agreement with Capsugel
      • 7.10.8.2. Development and Commercialization Agreement with Roche
  • 7.11. Somatoprim / DG3173 / COR-005 (Aspireo Pharmaceuticals / Cortendo AB)
    • 7.11.1. Product Overview
    • 7.11.2. Mechanism of Action
    • 7.11.3. History of Development
    • 7.11.4. Current Status of Development
    • 7.11.5. Key Clinical Trial Results
      • 7.11.5.1. Phase I Results: Somatoprim as Monotherapy
      • 7.11.5.2. Phase I Results: Somatoprim as Combination Therapy
      • 7.11.5.3. Phase II Results: Somatoprim as Monotherapy
    • 7.11.6. Collaborations
      • 7.11.6.1. Acquisition Agreement with Cortendo
      • 7.11.6.2. Strategic Advisory Agreement with Evotec
  • 7.12. ITF 2984 (Italfarmaco)
  • 7.13. CAM2029 (Camurus Pharmaceuticals / Novartis)
  • 7.14. Peptide Therapeutics Market: Acromegaly, 2015 - 2025

8. Peptide Therapeutics in Obesity

  • 8.1. Chapter Overview
  • 8.2. Obesity: Epidemiology
  • 8.3. Peptide Therapeutics in Obesity: Current Market Landscape
  • 8.4. Peptide Therapeutics in Obesity: Pipeline Analysis
  • 8.5. Peptide Therapeutics in Obesity: Distribution by Highest Phase of Development
  • 8.6. Peptide Therapeutics in Obesity: Distribution by Target Sub-Indication
  • 8.7. Peptide Therapeutics in Obesity: Distribution by Type of Analogue
  • 8.8. Peptide Therapeutics in Obesity: Distribution by Route of Administration
  • 8.9. Peptide Therapeutics in Obesity: Distribution by Dosage Frequency
  • 8.10. Saxenda® / Liraglutide 3 mg (Novo Nordisk)
    • 8.10.1. Product Overview
    • 8.10.2. History of Development
    • 8.10.3. Mechanism of Action
    • 8.10.4. Dosage Form, Regimen and Price
    • 8.10.5. Patents
    • 8.10.6. Current Status of Development
    • 8.10.7. SCALE™ Phase III Clinical Trial Program
    • 8.10.8. Key Clinical Trial Results
      • 8.10.8.1. SCALE™ Obesity and Prediabetes Trial
      • 8.10.8.2. SCALE™ Diabetes Clinical Trial Results
  • 8.11. Setmelanotide / RM-493 / BIM-22493 (Rhythm Pharmaceuticals)
  • 8.12. LY2944876 / TT-401 (Eli Lilly / Transition Therapeutics)
  • 8.13. Peptide Therapeutics Market: Obesity, 2015 - 2025

9. Peptide Therapeutics in Osteoporosis

  • 9.1. Chapter Overview
  • 9.2. Osteoporosis: Epidemiology
  • 9.3. Peptide Therapeutics in Osteoporosis: Current Market Landscape
  • 9.4. Peptide Therapeutics in Osteoporosis: Pipeline Analysis
  • 9.5. Peptide Therapeutics in Osteoporosis: Distribution by Highest Phase of Development
  • 9.6. Peptide Therapeutics in Osteoporosis: Distribution by Type of Analogue
  • 9.7. Peptide Therapeutics in Osteoporosis: Distribution by Route of Administration
  • 9.8. Peptide Therapeutics in Osteoporosis: Distribution by Dosage Frequency
  • 9.9. Peptide Therapeutics in Osteoporosis: Distribution by Type of Peptide
  • 9.10. TBRIA™ (Tarsa Therapeutics / Unigene Laboratories)
    • 9.10.1. Product Overview
    • 9.10.2. Mechanism of Action
    • 9.10.3. History of Development
    • 9.10.4. Peptelligence Technology
    • 9.10.5. Funding
    • 9.10.6. Patents
    • 9.10.7. Current Status of Development
    • 9.10.8. Key Clinical Trial results
      • 9.10.8.1. Meta-Analysis
      • 9.10.8.2. Phase III ORACAL Clinical Trial Results
      • 9.10.8.3. Phase II Results
    • 9.10.9. Collaborations
      • 9.10.9.1. Commercial Supply Agreement with QS Pharma
      • 9.10.9.2. License Agreement with Unigene Laboratories
  • 9.11. Abaloparatide / BIM44058 / BA058 (Radius Health / Teijin Pharma)
    • 9.11.1. Product Overview
    • 9.11.2. Mechanism of Action
    • 9.11.3. History of Development
    • 9.11.4. Abaloparatide-TD and 3M Microneedle Drug Delivery Technology
      • 9.11.4.1. Life Cycle Management
    • 9.11.5. Dosage Form and Regimen
    • 9.11.6. Manufacturing
    • 9.11.7. Patents
    • 9.11.8. Current Status of Development
    • 9.11.9. Key Clinical Trial Results
      • 9.11.9.1. Abaloparatide-SC: Phase III ACTIVE Results
      • 9.11.9.2. Abaloparatide-SC: Phase III ACTIVExtend Results
      • 9.11.9.3. Abaloparatide-TD: Phase II Results
    • 9.11.10. Collaborations
      • 9.11.10.1. Commercialization Strategy Agreement with Myrtle Potter & Company
      • 9.11.10.2. Clinical Trial Services Agreement with Nordic Bioscience
      • 9.11.10.3. Feasibility, Development and Clinical Supplies Agreement with 3M Drug Delivery Systems
      • 9.11.10.4. Development and Manufacturing Services Agreement with Lonza
      • 9.11.10.5. License Option Agreement with Novartis
      • 9.11.10.6. License Agreement with Ipsen Pharma
  • 9.12. Peptide Therapeutics Market: Osteoporosis, 2015 - 2025

10. Peptide Therapeutics in Other Metabolic Disorders

  • 10.1. Chapter Overview
  • 10.2. Peptide Therapeutics in Other Metabolic Disorders: Current Market Landscape
  • 10.3. Peptide Therapeutics in Other Metabolic Disorders: Pipeline Analysis
  • 10.4. Peptide Therapeutics in Other Metabolic Disorders: Distribution by Highest Phase of Development
  • 10.5. Peptide Therapeutics in Other Metabolic Disorders: Distribution by Type of Analogue
  • 10.6. Peptide Therapeutics in Other Metabolic Disorders: Distribution by Route of Administration
  • 10.7. Peptide Therapeutics in Other Metabolic Disorders: Distribution by Dosage Frequency
  • 10.8. SCENESSE® / Afamelanotide / CUV1647 (Clinuvel Pharmaceuticals)
    • 10.8.1. Product Overview
    • 10.8.2. Mechanism of Action
    • 10.8.3. History of Development
      • 10.8.3.1. Historical Timeline: FDA Related Events
      • 10.8.3.2. Historical Timeline: EC Related Events
      • 10.8.3.3. Historical Timeline: Swissmedic Related Events
      • 10.8.3.4. Historical Timeline: Italian Medicines Agency (AIFA) Related Events
      • 10.8.3.5. Historical Timeline: Australian Therapeutic Goods Administration (TGA) Related Events
    • 10.8.4. Dosage Form, Regimen and Price
    • 10.8.5. Manufacturing
    • 10.8.6. Target Population
    • 10.8.7. Historical Sales
    • 10.8.8. Current Status of Development
    • 10.8.9. Key Clinical Trial Results
      • 10.8.9.1. Phase III Results: US
      • 10.8.9.2. Phase III Results: Europe
    • 10.8.10. SCENESSE®: Key Publications
    • 10.8.11. Collaborations
      • 10.8.11.1. Joint Venture Agreement with Biotech Lab Singapore
      • 10.8.11.2. Manufacturing and License Agreement with SurModics (Evonik)
  • 10.9. Signifor® / Pasireotide (Novartis)
    • 10.9.1. Product Overview
    • 10.9.2. History of Development
    • 10.9.3. Mechanism of Action
    • 10.9.4. Dosage Form, Regimen and Price
    • 10.9.5. Patents
    • 10.9.6. Historical Sales
    • 10.9.7. Target Population
    • 10.9.8. Current Status of Development
    • 10.9.9. Key Clinical Trial Results
  • 10.10. AEM-28 (LipimetiX Development)
  • 10.11. BMN-111 / Vosoritide (BioMarin Pharmaceutical)
  • 10.12. AZP-131 (Alize Pharma)
  • 10.13. Peptide Therapeutics Market: Other Metabolic Disorders, 2015 - 2025

11. Key Technology Platforms

  • 11.1. Chapter Overview
    • 11.1.1. Peptide Technology Platforms: Distribution by Key Features
  • 11.2. ArisCrown Technology (ArisGen)
    • 11.2.1. Company Overview
    • 11.2.2. Technology Overview
    • 11.2.3. Mechanism of Action
    • 11.2.4. Advantages
    • 11.2.5. Peptide Therapeutics based on the ArisCrown Technology
    • 11.2.6. Collaborations
  • 11.3. Chimeric Apo E Mimetic Peptide (CHAMP) Technology (LipimetiX Development)
    • 11.3.1. Company Overview
    • 11.3.2. Technology Overview
    • 11.3.3. Mechanism of Action
    • 11.3.4. Peptide Therapeutics based on the CHAMP Technology
    • 11.3.5. Patents
    • 11.3.6. Collaborations
  • 11.4. Glide SDI® (Solid Dose Injector) (Glide Technologies)
    • 11.4.1. Company Overview
    • 11.4.2. Technology Overview
    • 11.4.3. Components
    • 11.4.4. Process of Drug Formulation
    • 11.4.5. Mechanism of Drug Delivery
    • 11.4.6. Advantages
    • 11.4.7. Peptide Therapeutics based on the Glide SDI® Technology
    • 11.4.8. Collaborations
    • 11.4.9. Funding
  • 11.5. FluidCrystal® Injection Depot (Camurus Pharmaceuticals)
    • 11.5.1. Company Overview
    • 11.5.2. Technology Overview
    • 11.5.3. Mechanism of Action
    • 11.5.4. Advantages
    • 11.5.5. Peptide Therapeutics based on the FluidCrystal® Injection Depot Technology
    • 11.5.6. Collaborations
  • 11.6. PC-DAC™ (ConjuChem)
    • 11.6.1. Company Overview
    • 11.6.2. Technology Overview
    • 11.6.3. Mechanism of Action
    • 11.6.4. Advantages
    • 11.6.5. Peptide Therapeutics based on the PC-DAC™ Technology
    • 11.6.6. Collaborations
  • 11.7. PharmFilm® Technology Platform (MonoSol Rx)
    • 11.7.1. Company Overview
    • 11.7.2. Technology Overview
    • 11.7.3. Mechanism of Action
    • 11.7.4. Advantages
    • 11.7.5. Patents
    • 11.7.6. Peptide Therapeutics based on the PharmFilm® Technology
    • 11.7.7. Collaborations
  • 11.8. Intarcia Technology Platform (Intarcia Therapeutics)
    • 11.8.1. Company Overview
    • 11.8.2. Technology Overview
    • 11.8.3. Mechanism of Action
    • 11.8.4. Advantages
    • 11.8.5. Peptide Therapeutics based on the Intarcia Technology
    • 11.8.6. Collaborations
  • 11.9. Eligen® Technology (Emisphere Technologies)
    • 11.9.1. Company Overview
    • 11.9.2. Technology Overview
    • 11.9.3. Mechanism of Action
    • 11.9.4. Advantages
    • 11.9.5. Peptide Therapeutics based on the Eligen® Technology
    • 11.9.6. Collaborations
  • 11.10. XTEN® Technology (Amunix)
    • 11.10.1. Company Overview
    • 11.10.2. Technology Overview
    • 11.10.3. Mechanism of Action
    • 11.10.4. Advantages
    • 11.10.5. Patents
    • 11.10.6. XTEN® Versus PEG
    • 11.10.7. Peptide Therapeutics Based on the XTEN® Technology
    • 11.10.8. Collaborations
  • 11.11. Axcess™ Oral Drug Delivery Technology (Proxima Concepts / Diabetology)
    • 11.11.1. Company Overview
    • 11.11.2. Technology Overview
    • 11.11.3. Mechanism of Action
    • 11.11.4. Advantages
    • 11.11.5. Peptide Therapeutics based on the Axcess™ Technology
    • 11.11.6. Patents
    • 11.11.7. Collaborations
  • 11.12. POD™ (Protein Oral Delivery) Technology (Oramed Pharmaceuticals)
    • 11.12.1. Company Overview
    • 11.12.2. Technology Overview
    • 11.12.3. Mechanism of Action
    • 11.12.4. Advantages
    • 11.12.5. Patents
    • 11.12.6. Peptide Therapeutics Based on the POD™ Technology
    • 11.12.7. Collaborations
  • 11.13. Transient Permeability Enhancer (TPE®) Technology (Chiasma)
    • 11.13.1. Company Overview
    • 11.13.2. Technology Overview
    • 11.13.3. Mechanism of Action
    • 11.13.4. Advantages
    • 11.13.5. Peptide Therapeutics based on the TPE® Technology
    • 11.13.6. Collaborations
  • 11.14. SmartDepot™ (Peptron)
    • 11.14.1. Company Overview
    • 11.14.2. Technology Overview
    • 11.14.3. Mechanism of Action
    • 11.14.4. Advantages
    • 11.14.5. Patents
    • 11.14.6. Peptide Therapeutics based on the SmartDepot™ Technology
    • 11.14.7. Collaborations
  • 11.15. 3M Microneedle Drug Delivery Technology (3M Drug Delivery Systems)
    • 11.15.1. Company Overview
    • 11.15.2. Technology Overview
    • 11.15.3. Mechanism of Action
      • 11.15.3.1. Solid Microneedle Technology
      • 11.15.3.2. Hollow Microneedle Technology
    • 11.15.4. Advantages
      • 11.15.4.1. Solid Microneedle Technology
      • 11.15.4.2. Hollow Microneedle Technology
    • 11.15.5. Peptide Therapeutics based on the 3M Microneedle Drug Delivery Technology
    • 11.15.6. Collaborations
  • 11.16. Gastrointestinal Permeation Enhancement Technology (GIPET®) (Merrion Pharmaceuticals)
    • 11.16.1. Company Overview
    • 11.16.2. Technology Overview
    • 11.16.3. Mechanism of Action
    • 11.16.4. Advantages
    • 11.16.5. Patents
    • 11.16.6. Peptide Therapeutics based on the GIPET® Technology
    • 11.16.7. Collaborations
  • 11.17. LAPSCOVERY™ Technology (Hanmi Pharmaceuticals)
    • 11.17.1. Company Overview
    • 11.17.2. Technology Overview
    • 11.17.3. Mechanism of Action
    • 11.17.4. Advantages
    • 11.17.5. Patents
    • 11.17.6. Peptide Therapeutics based on the LAPSCOVERY™ Technology
    • 11.17.7. Collaborations
  • 11.18. Peptelligence™ Technology (Unigene Laboratories / Enteris Biopharma)
    • 11.18.1. Company Overview
    • 11.18.2. Technology Overview
    • 11.18.3. Components and Functions
      • 11.18.3.1. Tablet Design
      • 11.18.3.2. Mechanism of Drug Delivery
    • 11.18.4. Advantages
    • 11.18.5. Patents
    • 11.18.6. Peptide Therapeutics based on the Peptelligence™ Technology
    • 11.18.7. Collaborations

12. Interview Transcripts

  • 12.1. Chapter Overview
  • 12.2. Andrew Mallon, CEO, Calista Therapeutics
  • 12.3. Andrew Parker, CEO, ArisGen
  • 12.4. John Dodd, VP Discovery and Research, Palatin Technologies
  • 12.5. Dennis Goldberg, President, LipimetiX Development

13. Conclusion

  • 13.1. Peptide Therapeutics Has Gradually Gained the Attention of Drug Developers
  • 13.2. Metabolic Disorders is One of the Prime Focus Areas
  • 13.3. In Addition to Diabetes, Obesity, Acromegaly and Osteoporosis, Research is Underway on Several Lesser-known Disorders
  • 13.4. Technological Advancements Have Emerged As Strong Enablers to the Ongoing Growth
  • 13.5. Challenges Remain; Innovative Approaches Will Continue to Sustain the Momentum
  • 13.6. Overall Opportunity is Big; We Project a ~10 % Growth in Our Base Scenario

14. Appendix 1: Tabulated Data

15. Appendix 2: List of Companies and Organizations

List of Figures

  • Figure 3.1: Peptide Therapeutics: Methods of Chemical Synthesis
  • Figure 3.2: Solid Phase Peptide Synthesis: Steps Involved
  • Figure 4.1: Metabolic Disorders: Classification
  • Figure 4.2: Amino Acid Metabolism Disorders: Classification
  • Figure 4.3: Porphyria: Classification
  • Figure 4.4: Lipid Metabolism Disorders: Classification
  • Figure 4.5: Peroxisomal Disorders: Classification
  • Figure 4.6: Purine and Pyrimidine Disorders: Classification
  • Figure 4.7: Carbohydrate Metabolism Disorders: Classification
  • Figure 5.1: Peptide Therapeutics in Metabolic Disorders: Distribution by Highest Phase of Development
  • Figure 5.2: Peptide Therapeutics in Metabolic Disorders: Distribution by Indication
  • Figure 5.3: Peptide Therapeutics in Metabolic Disorders: Distribution by Indication Across Marketed, Clinical and Preclinical Phases of Development
  • Figure 5.4: Peptide Therapeutics in Metabolic Disorders: Distribution by Route of Administration
  • Figure 5.5: Peptide Therapeutics in Metabolic Disorders: Distribution by Route of Administration across Marketed, Clinical and Preclinical Phases of Development
  • Figure 5.6: Peptide Therapeutics in Metabolic Disorders: Distribution by Type of Analogue
  • Figure 5.7: Peptide Therapeutics in Metabolic Disorders: Distribution by Type of Analogue across Marketed, Clinical and Preclinical Phases of Development
  • Figure 5.8: Peptide Therapeutics in Metabolic Disorders: Distribution by Type of Peptide
  • Figure 5.9: Peptide Therapeutics in Metabolic Disorders: Distribution by Dosage Frequency
  • Figure 5.10: Peptide Therapeutics in Metabolic Disorders: Distribution by Dosage Frequency across Daily, Weekly, Monthly, Semi Annually and Annually Categories
  • Figure 5.11: Peptide Therapeutics Market (USD Billion): Metabolic Disorders, 2015 - 2025 (Base Scenario)
  • Figure 6.1: Diabetes: Worldwide Prevalence and Diagnosis (Million)
  • Figure 6.2: Diabetes: Prevalence by Region / Country (Million)
  • Figure 6.3: Diabetes: Diagnosed Cases by Region / Country (Million)
  • Figure 6.4: Peptide Therapeutics in Diabetes: Distribution by Highest Phase of Development
  • Figure 6.5: Peptide Therapeutics in Diabetes: Distribution by Target Sub-Indication
  • Figure 6.6: Peptide Therapeutics in Diabetes: Distribution by Type of Analogue
  • Figure 6.7: Peptide Therapeutics in Diabetes: Distribution by Route of Administration
  • Figure 6.8: Peptide Therapeutics in Diabetes: Distribution by Dosage Frequency
  • Figure 6.9: Peptide Therapeutics in Diabetes: Distribution by Type of Peptide
  • Figure 6.10: Lyxumia® (Lixisenatide): Historical Timeline
  • Figure 6.11: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: Historical Timeline
  • Figure 6.12: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: Historical Sales (USD Million)
  • Figure 6.13: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: Regional Distribution of Historical Sales (USD Million)
  • Figure 6.14: ITCA 650: FREEDOM-1 and FREDDOM-1 HBL Clinical Trials
  • Figure 6.15: Peptide p277 / AVE-0277 / DiaPep277: Development Timeline (Post Acquisition by Andromeda)
  • Figure 6.16: Peptide Therapeutics Market (USD Million): Diabetes, 2015 - 2025: (Base Scenario)
  • Figure 7.1: Peptide Therapeutics in Acromegaly: Distribution by Highest Phase of Development
  • Figure 7.2: Peptide Therapeutics in Acromegaly: Distribution by the Route of Administration
  • Figure 7.3: Peptide Therapeutics in Acromegaly: Distribution by Dosage Frequency
  • Figure 7.4: Signifor® LAR: Administration Procedure
  • Figure 7.5: Signifor® LAR: Key Clinical Trials
  • Figure 7.6: Mycapssa: Development Timeline
  • Figure 7.7: Peptide Therapeutics Market (USD Million): Acromegaly, 2015 - 2025: (Base Scenario)
  • Figure 8.1: Peptide Therapeutics in Obesity: Distribution by Highest Phase of Development
  • Figure 8.2: Peptide Therapeutics in Obesity: Distribution by Target Sub-Indication
  • Figure 8.3: Peptide Therapeutics in Obesity: Distribution by Type of Analogue
  • Figure 8.4: Peptide Therapeutics in Obesity: Distribution by Route of Administration
  • Figure 8.5: Peptide Therapeutics in Obesity: Distribution by Dosage Frequency
  • Figure 8.6: Saxenda® / Liraglutide rDNA origin / Liraglutide 3 mg: Administration Procedure
  • Figure 8.7: Peptide Therapeutics Market (USD Million): Obesity, 2015-2025 (Base Scenario)
  • Figure 9.1: Peptide Therapeutics in Osteoporosis: Distribution by Highest Phase of Development
  • Figure 9.2: Peptide Therapeutics in Osteoporosis: Distribution by Type of Analogue
  • Figure 9.3: Peptide Therapeutics in Osteoporosis: Distribution by Route of Administration
  • Figure 9.4: Peptide Therapeutics in Osteoporosis: Distribution by Dosage Frequency
  • Figure 9.5: Peptide Therapeutics in Osteoporosis: Distribution by Type of Peptide
  • Figure 9.6: Peptide Therapeutics Market (USD Million): Osteoporosis, 2015 - 2025: (Base Scenario)
  • Figure 10.1: Peptide Therapeutics in Other Metabolic Disorders: Distribution by Highest Phase of Development
  • Figure 10.2: Peptide Therapeutics in Other Metabolic Disorders: Distribution by Type of Analogue
  • Figure 10.3: Peptide Therapeutics in Other Metabolic Disorders: Distribution by Route of Administration
  • Figure 10.4: Peptide Therapeutics in Other Metabolic Disorders: Distribution by Dosage Frequency
  • Figure 10.5: SCENESSE® / Afamelanotide / CUV1647: Mechanism of Action
  • Figure 10.6: SCENESSE® / Afamelanotide / CUV1647: FDA / US Related Events
  • Figure 10.7: SCENESSE® / Afamelanotide / CUV1647: EC / EMA / Europe Related Events
  • Figure 10.8: Signifor® / Pasireotide: Mechanism of Action
  • Figure 10.9: Signifor® / Pasireotide: Dosing and Administration
  • Figure 10.10: Signifor® / Pasireotide: Dose Formulations
  • Figure 10.11: Signifor® Sales (USD Million), 2012 - 2014
  • Figure 10.12: Peptide Therapeutics Market (USD Million): Other Metabolic Disorders, 2015 - 2025 (Base Scenario)
  • Figure 11.1: Peptide Technology Platforms: Distribution by Key Features
  • Figure 11.2: ArisCrown Technology: Mechanism of Action
  • Figure 11.3: Glide SDI® System: Key Components
  • Figure 11.4: Glide SDI®: Drug Formulation Process
  • Figure 11.5: FluidCrystal® Injection Depot: Mechanism of Action
  • Figure 11.6: Intarcia Technology: Mechanism of Action
  • Figure 11.7: XTEN® Technology Platform: Genetic Fusion of XTEN® to Peptides
  • Figure 11.8: XTEN® Technology Platform: Chemical Conjugation of XTEN to Peptides
  • Figure 11.9: Axcess™ Technology: Components of the Capsule
  • Figure 11.10: Transient Permeability Enhancer (TPE®) Technology: Mechanism of Action
  • Figure 11.11: SmartDepot™ Technology: Components
  • Figure 11.12: SmartDepot™ Technology: Mechanism of Action
  • Figure 11.13: Multifunctional Role of Absorption Enhancer in GIPET®
  • Figure 11.14: LAPSCOVERY™ Technology: Components
  • Figure 11.15: Peptelligence™ Technology: Components of Enteric Coated Tablet
  • Figure 11.16: Peptelligence™ Technology: Mechanism of Drug Delivery
  • Figure 13.1: Peptide Therapeutic Market (USD Billion): Metabolic Disorders- 2015, 2020 and 2025

List of Tables

  • Table 4.1: Metabolic Disorders: Most Prominent Diseases
  • Table 5.1: Peptide Therapeutics in Metabolic Disorders: Marketed Drugs
  • Table 5.2: Peptide Therapeutics in Metabolic Disorders: Clinical Pipeline
  • Table 5.3: Peptide Therapeutics in Metabolic Disorders: Preclinical / Discovery Pipeline
  • Table 5.4: Dosage Frequency: Categories
  • Table 5.5: Metabolic Disorders: Peptide Therapeutics and Current Development Phase
  • Table 6.1: Peptide Therapeutics in Diabetes: Pipeline
  • Table 6.2: Lyxumia® (Lixisenatide) as Combination Treatment
  • Table 6.3: Lyxumia®: Price
  • Table 6.4: Lyxumia® (Lixisenatide): Price Comparison
  • Table 6.5: Lyxumia® (Lixisenatide): Current Status of Development
  • Table 6.6: Lyxumia® (Lixisenatide): GetGoal Phase III Clinical Program
  • Table 6.7: Lyxumia® (Lixisenatide): GetGoal F-1Phase III Results
  • Table 6.8: Lyxumia® (Lixisenatide): ELIXA Clinical Trial Results
  • Table 6.9: Lyxumia® (Lixisenatide): GetGoal Duo-2 Clinical Trial Results
  • Table 6.10: Lyxumia® (Lixisenatide): Adverse Events Reported in GetGoal Duo-2 Clinical Trial
  • Table 6.11: Lyxumia® (Lixisenatide) Versus Liraglutide: Phase II Results
  • Table 6.12: Lyxumia® (Lixisenatide) Versus Liraglutide: Phase II Study Adverse Events
  • Table 6.13: Lyxumia® (Lixisenatide) Versus Liraglutide Phase II study: Amylase Levels from baseline
  • Table 6.14: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: Patents
  • Table 6.15: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: Patent Expiry
  • Table 6.16: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: Ingredients
  • Table 6.17: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: Microsphere Composition
  • Table 6.18: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: Diluent Composition
  • Table 6.19: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: Dosage Forms
  • Table 6.20: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: Current Status of Development
  • Table 6.21: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: DURATION Phase III Clinical Trial Program
  • Table 6.22: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: DURATION-2 Phase III Study Results
  • Table 6.23: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: DURATION-3 Study Adverse Events
  • Table 6.24: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: DURATION-4 Study Results
  • Table 6.25: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: DURATION-5 Study Results
  • Table 6.26: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: DURATION-6 Study Adverse Events
  • Table 6.27: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: DURATION-NEO Study Results
  • Table 6.28: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: DURATION-NEO-1 Study Adverse Events
  • Table 6.29: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: DURATION-NEO-1 Study Gastrointestinal Adverse Events
  • Table 6.30: Semaglutide: Current Status of Development
  • Table 6.31: SUSTAIN Clinical Program: Key Characteristics
  • Table 6.32: Semaglutide: SUSTAIN 3 Clinical Trial Results
  • Table 6.33: ITCA 650: FREEDOM Clinical Trial Development Program
  • Table 6.34: ITCA 650: Current Status of Development
  • Table 6.35: PEX 168: Current Status of Development
  • Table 6.36: PEX 168: Clinical Trial Results
  • Table 6.37: Peptide p277 / AVE-0277 / DiaPep277: DIA-AID 1 Clinical Trial Results
  • Table 6.38: Peptide p277/AVE-0277/DiaPep277: DIA-AID 1 Extension study results
  • Table 6.39: Efpeglenatide / HM11260C: Current Status of Development
  • Table 6.40: Efpeglenatide/ HM11260C: Phase II Clinical Trial Arms
  • Table 6.41: Efpeglenatide/ HM11260C: Phase Ib Clinical Trial Arms
  • Table 6.42: Efpeglenatide / HM11260C: Phase Ib Clinical Trial Arms
  • Table 6.43: Efpeglenatide / HM11260C: Phase Ib Clinical Trial Results
  • Table 6.44: Efpeglenatide / HM11260C: Phase II (20-week) Study, Dose Regimens
  • Table 6.45: Efpeglenatide / HM11260C: Phase II (20-week) Study, Results
  • Table 6.46: Efpeglenatide / HM11260C: Phase II (20-week) Study, Adverse Events
  • Table 6.47: Efpeglenatide / HM11260C: Phase II (12-week) Study, Arms
  • Table 6.48: Efpeglenatide / HM11260C: Phase II (12-week) Study, Results
  • Table 6.49: Efpeglenatide / HM11260C: Phase II (12-week) Study, Adverse Events
  • Table 6.50: PB1023: Product Overview
  • Table 6.51: RO6811135: Product Overview
  • Table 6.52: CJC-1134-PC: Product Overview
  • Table 7.1: Peptide Therapeutics in Acromegaly: Pipeline
  • Table 7.2: Signifor® LAR: Drug Composition
  • Table 7.3: Signifor® LAR: Diluent Composition
  • Table 7.4: Signifor® LAR: Patents
  • Table 7.5: Signifor® LAR: Current Status of Development
  • Table 7.6: Signifor® LAR: Phase III C2305 Trial Adverse Events
  • Table 7.7: Signifor® LAR: Phase III C2402 Study Results
  • Table 7.8: Signifor® LAR trial, C2305: Adverse Events
  • Table 7.9: Mycapssa™ / Octreolin™ / Oral Octreotide: Current Status of Development
  • Table 7.10: Mycapssa™ / Oral Octreotide: Phase III Study Results (Response Rates to Injectable Somatostatin Analogues)
  • Table 7.11: Mycapssa™ / Oral Octreotide: Phase III Study Results (Response Rates to Oral Octreotide)
  • Table 7.12: Somatoprim / DG3173 / COR-005: Current Status of Development
  • Table 7.13: ITF2984: Product Overview
  • Table 7.14: CAM2029: Product Overview
  • Table 8.1: Peptide Therapeutics in Obesity: Pipeline
  • Table 8.2: Saxenda® / Liraglutide 3 mg: Pharmaceutical Ingredients in 1 ml Solution
  • Table 8.3: Saxenda® / Liraglutide 3 mg: Dose Escalation Schedule
  • Table 8.4: Saxenda® / Liraglutide rDNA origin / Liraglutide 3 mg: Patents
  • Table 8.5: Saxenda® / Liraglutide rDNA origin / Liraglutide 3 mg: Phase IIIa SCALE™ Trial Program
  • Table 8.6: Saxenda® / Liraglutide 3 mg: Phase IIIa SCALE Obesity and Prediabetes Study Results (56-week)
  • Table 8.7: Saxenda® / Liraglutide rDNA origin / Liraglutide 3 mg: Phase IIIa SCALE Obesity and Prediabetes 3-year Extension Study Results
  • Table 8.8: Saxenda® / Liraglutide 3 mg: Phase III SCALE™ Obesity and Prediabetes, Proportion of Responders (56-week)
  • Table 8.9: Saxenda® / Liraglutide rDNA origin / Liraglutide 3 mg: SCALE™ Phase III Obesity and Prediabetes Study Adverse Events
  • Table 8.10: Saxenda® / Liraglutide 3 mg: Phase III SCALE™ Diabetes Study Results (56-week)
  • Table 8.11: Saxenda® / Liraglutide 3 mg: SCALE™ Phase III Diabetes Study Adverse Events
  • Table 8.12: Setmelanotide / RM-493 / BIM-22493: Product Overview
  • Table 8.13: Setmelanotide / RM-493 / BIM-22493: Funding
  • Table 8.14: LY2944876 / TT-401: Product Overview
  • Table 9.1: Peptide Therapeutics in Osteoporosis: Pipeline
  • Table 9.2: TBRIA™: Phase III ORACAL Clinical Trial Results
  • Table 9.3: Abaloparatide / BIM44058 / BA058: Patent Information
  • Table 9.4: Abaloparatide / BIM44058 / BA058: ACTIVE Study Results
  • Table 9.5: Abaloparatide / BIM44058 / BA058: ACTIVE AND ACTIVExtend Clinical Trial Results (Fracture Reduction over 25-month period)
  • Table 9.6: Abaloparatide / BIM44058 / BA058: ACTIVE AND ACTIVExtend Clinical Trial Results (Increase in BMD over 25-month Period)
  • Table 9.7: Abaloparatide / BIM44058/ BA058: ACTIVE AND ACTIVExtend Clinical Trial Results (Adverse events reported over 25-month period)
  • Table 10.1: Peptide Therapeutics in Other Metabolic Disorders: Pipeline
  • Table 10.2: SCENESSE® / Afamelanotide / CUV1647: Current Status of Development
  • Table 10.3: Signifor® / Pasireotide: Binding Affinity to the Five Human SSTR Subtypes
  • Table 10.4: Signifor® / Pasireotide: Price
  • Table 10.5: Signifor® / Pasireotide: Patents
  • Table 10.6: Signifor® / Pasireotide: Additional Patents
  • Table 10.7: Signifor® / Pasireotide: Current Status of Development
  • Table 10.8: Signifor® / Pasireotide: Phase III Study Results (24-Hour Urinary Free Cortisol (UFC) Study Results at Month 6 in Patients with Cushing's disease)
  • Table 10.9: AEM-28: Product Overview
  • Table 10.10: BMN-111 / Vosoritide: Product Overview
  • Table 10.11: AZP-531: Product Overview
  • Table 11.1: Peptide Therapeutics in Metabolic Disorders: Technology Platforms
  • Table 11.2: ArisCrown Technology: Peptide Therapeutics for Metabolic Disorders
  • Table 11.3: CHAMP Technology: Peptide Therapeutics for Metabolic Disorders
  • Table 11.4: Glide SDI® (Solid Dose Injector): Peptide Therapeutics for Metabolic Disorders
  • Table 11.5: XTEN® Platform: Patent Status
  • Table 11.6: XTEN® vs PEG: Comparison of Key Features
  • Table 11.7: XTEN® Technology: Drugs Targeting Metabolic Diseases
  • Table 11.8: Axcess™ Technology: Peptide Therapeutics for Metabolic Disorders
  • Table 11.9: Axcess™ Technology: Patent Info
  • Table 11.10: POD™ Patent Status
  • Table 11.11: Transient Permeability Enhancer (TPE®) Technology: Pipeline Drugs Targeting Metabolic Disorders
  • Table 11.12: SmartDepot™ Technology: Patent Info
  • Table 11.13: Smart Depot™ Technology: Drugs Targeting Metabolic Diseases
  • Table 11.14: GIPET® Technology: Platforms
  • Table 11.15: GIPET® Technology: Molecules Tested
  • Table 11.16: LAPSCOVERY™ Technology: Drugs Targeting Metabolic Diseases
  • Table 11.17: Peptelligence ™ Technology: Patent Info
  • Table 14.1: Peptide Therapeutics in Metabolic Disorders: Distribution by Highest Phase of Development
  • Table 14.2: Peptide Therapeutics in Metabolic Disorders: Distribution by Indication
  • Table 14.3: Peptide Therapeutics in Metabolic Disorders: Distribution by Indication across Marketed, Clinical and Preclinical phases of development
  • Table 14.4: Peptide Therapeutics in Metabolic Disorders: Distribution by Route of Administration
  • Table 14.5: Peptide Therapeutics in Metabolic Disorders: Distribution by Route of Administration across Marketed, Clinical and Preclinical phases of development
  • Table 14.6: Peptide Therapeutics in Metabolic Disorders: Distribution by Type of Analogue
  • Table 14.7: Peptide Therapeutics in Metabolic Disorders: Distribution by Type of Analogue across Marketed, Clinical and Preclinical Phases of Development
  • Table 14.8: Peptide Therapeutics in Metabolic Disorders: Distribution by Type of Peptide
  • Table 14.9: Peptide Therapeutics in Metabolic Disorders: Distribution by Dosage Frequency
  • Table 14.10: Peptide Therapeutics in Metabolic Disorders: Distribution by Dosage Frequency across Daily, Weekly, Monthly, Semi Annually and Annually Categories
  • Table 14.11: Peptide Therapeutics Market (USD Billion): Metabolic Disorders, 2015 - 2025 (Base Scenario)
  • Table 14.12: Peptide Therapeutics Market (USD Billion): Metabolic Disorders, 2015 - 2025 (Optimistic Scenario)
  • Table 14.13: Peptide Therapeutics Market (USD Billion): Metabolic Disorders, 2015 - 2025 (Conservative Scenario)
  • Table 14.14: Diabetes: Worldwide Prevalence and Diagnosis (Million)
  • Table 14.15: Diabetes: Prevalence by Region / Country (Million)
  • Table 14.16: Diabetes: Diagnosed Cases by Region / Country (Million)
  • Table 14.17: Peptide Therapeutics in Diabetes: Distribution by Highest Phase of Development
  • Table 14.18: Peptide Therapeutics in Diabetes: Distribution by the Target Sub-Indication
  • Table 14.19: Peptide Therapeutics in Diabetes: Distribution by the Type of Analogue
  • Table 14.20: Peptide Therapeutics in Diabetes: Distribution by the Route of Administration
  • Table 14.21: Peptide Therapeutics in Diabetes: Distribution by Dosage Frequency
  • Table 14.22: Peptide Therapeutics in Diabetes: Distribution by Type of Peptide
  • Table 14.23: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: Historical Sales (USD Million)
  • Table 14.24: BYDUREON® / Exenatide Once Weekly / Exenatide Extended Release: Regional Distribution of Historical Sales (USD Million)
  • Table 14.25: Peptide Therapeutics Market (USD Million): Diabetes Sales, 2015 - 2025 (Base Scenario)
  • Table 14.26: Peptide Therapeutics Market (USD Million): Diabetes Sales, 2015 - 2025 (Optimistic Scenario)
  • Table 14.27: Peptide Therapeutics Market (USD Million): Diabetes Sales, 2015 - 2025 (Conservative Scenario)
  • Table 14.28: Peptide Therapeutics in Acromegaly: Distribution by Highest Phase of Development
  • Table 14.29: Peptide Therapeutics in Acromegaly: Distribution by the Route of Administration
  • Table 14.30: Peptide Therapeutics in Acromegaly: Distribution by Dosage Frequency
  • Table 14.31: Peptide Therapeutics Market (USD Million): Acromegaly, 2015 - 2025: (Base Scenario)
  • Table 14.32: Peptide Therapeutics Market (USD Million): Acromegaly, 2015 - 2025: (Optimistic Scenario)
  • Table 14.33: Peptide Therapeutics Market (USD Million): Acromegaly, 2015 - 2025: (Conservative Scenario)
  • Table 14.34: Peptide Therapeutics in Obesity: Distribution by Highest Phase of Development
  • Table 14.35: Peptide Therapeutics in Obesity: Distribution by the Target Sub-Indication
  • Table 14.36: Peptide Therapeutics in Obesity: Distribution by Route of Administration
  • Table 14.37: Peptide Therapeutics in Obesity: Distribution by Dosage Frequency
  • Table 14.38: Peptide Therapeutics in Obesity: Distribution by Type of Analogue
  • Table 14.39: Peptide Therapeutics Market (USD Million): Obesity, 2015 - 2025 (Base Scenario)
  • Table 14.40: Peptide Therapeutics Market (USD Million): Obesity, 2015 - 2025 (Optimistic Scenario)
  • Table 14.41: Peptide Therapeutics Market (USD Million): Obesity, 2015 - 2025 (Conservative Scenario)
  • Table 14.42: Peptide Therapeutics in Osteoporosis: Distribution by Highest Phase of Development
  • Table 14.43: Peptide Therapeutics in Osteoporosis: Distribution by Type of Analogue
  • Table 14.44: Peptide Therapeutics in Osteoporosis: Distribution by Route of Administration
  • Table 14.45: Peptide Therapeutics in Osteoporosis: Distribution by Type of Peptide
  • Table 14.46: Peptide Therapeutics in Osteoporosis: Distribution by Dosage Frequency
  • Table 14.47: Peptide Therapeutics Market (USD Million): Osteoporosis, 2015 - 2025: (Base Scenario)
  • Table 14.48: Peptide Therapeutics Market (USD Million): Osteoporosis, 2015 - 2025: (Optimistic Scenario)
  • Table 14.49: Peptide Therapeutics Market (USD Million): Osteoporosis, 2015 - 2025: (Conservative Scenario)
  • Table 14.50: Peptide Therapeutics in Other Metabolic Disorders: Distribution by Highest Phase of Development
  • Table 14.51: Peptide Therapeutics in Osteoporosis: Distribution by Type of Analogue
  • Table 14.52: Peptide Therapeutics in Other Metabolic Disorders: Distribution by Route of Administration
  • Table 14.53: Peptide Therapeutics in Other Metabolic Disorders: Distribution by Dosage Frequency
  • Table 14.54: Signifor Sales (USD Million), 2012 - 2014
  • Table 14.55: Peptide Therapeutics Market (USD Million): Other Metabolic Disorders, 2015 - 2025 (Base Scenario)
  • Table 14.56: Peptide Therapeutics Market (USD Million): Other Metabolic Disorders, 2015 - 2025 (Optimistic Scenario)
  • Table 14.57: Peptide Therapeutics Market (USD Million): Other Metabolic Disorders, 2015 - 2025 (Conservative Scenario)
  • Table 14.58: Peptide Technology Platforms: Distribution by Key Features
  • Table 14.59: Peptide Therapeutic Market (USD Billion): Metabolic Disorders- 2015, 2020 and 2025

List of Companies

The following companies and organizations have been mentioned in this report.

  • 1. 3M Drug Delivery Systems
  • 2. 7 Med Health Ventures
  • 3. Abingworth
  • 4. Aileron Therapeutics
  • 5. Albany Molecular Research
  • 6. Alize Pharma
  • 7. Alkermes
  • 8. American Diabetes Association
  • 9. Amunix
  • 10. Amylin Pharmaceuticals
  • 11. Andromeda Biotech
  • 12. APEPTICO
  • 13. Apitope
  • 14. ARCH Venture Partners
  • 15. ArisGen
  • 16. Asahi Kasei Pharma
  • 17. Aspireo Pharmaceuticals
  • 18. AstraZeneca
  • 19. AZAD Pharma
  • 20. Biodel
  • 21. Biogen Idec
  • 22. Biolaxy
  • 23. BioMarin Pharmaceutical
  • 24. Biotech Lab Singapore
  • 25. Bristol Myers Squibb
  • 26. Bone Medical
  • 27. Calista Therapeutics
  • 28. Camurus Pharmaceuticals
  • 29. Capstone Therapeutics
  • 30. Capsugel
  • 31. CEMA
  • 32. Chiasma
  • 33. Cilian
  • 34. Clal Biotechnology Industries
  • 35. Clinuvel pharmaceuticals
  • 36. ConjuChem
  • 37. Cortendo AB
  • 38. CureDM
  • 39. DeveloGen
  • 40. Diabetology
  • 41. Diartis Pharmaceuticals
  • 42. Dong-A ST Co.
  • 43. Elan Corporation
  • 44. Elli Lilly and Company
  • 45. EMD Serono
  • 46. Emisphere Technologies
  • 47. Enteris BioPharma
  • 48. Erasmus Medical Center
  • 49. European Association for the Study of Diabetes (EASD)
  • 50. Evotech
  • 51. F2 Capital
  • 52. F3 Ventures
  • 53. Farallon Capital Management
  • 54. Foresee Pharmaceuticals
  • 55. Foresite Capital
  • 56. Franklin Templeton
  • 57. Fred Alger Management
  • 58. Fredric Price
  • 59. Friedrich Schiller University
  • 60. Genentech
  • 61. GlaxoSmithKline
  • 62. Glide Technologies
  • 64. Hadassah University Medical Center
  • 65. Hanmi Pharmaceuticals
  • 66. Hefei Tianhui Incubator of Technologies Co.
  • 67. Horizon Pharma
  • 68. Hovione
  • 69. Hygea VCT
  • 70. Hyperison Therapeutics
  • 71. Impel NeuroPharma
  • 72. Intarcia Therpeutics
  • 73. International Diabetes Federation (IDF)
  • 74. Invesco Perpetual
  • 75. Ipsen
  • 76. Italfarmaco
  • 77. Janssen Pharmaceuticals
  • 78. Jiangsu Hansoh Pharmaceutical Co., Ltd
  • 79. KeyBioScience
  • 80. Lanthio Pharma
  • 81. LipimetiX Development
  • 82. Longevity Biotech
  • 83. Lonza Group
  • 84. MedImmune
  • 85. Merck
  • 86. Merrion Pharmaceuticals
  • 87. MidaSol Therapeutics
  • 88. Midatech
  • 89. Monosol Rx
  • 90. MPM Capital
  • 91. MVM Life Science Partners
  • 92. Myrtle Potter & Company
  • 93. Naia Pharmaceuticals
  • 94. New Enterprise Associates
  • 95. New Leaf Venture Partners
  • 96. New Paradigm Therapeutics
  • 97. NOD Pharmaceuticals
  • 98. Nordic Bioscience
  • 99. Novartis
  • 100. Novo Nordisk
  • 101. Numab
  • 102. Nypro Healthcare
  • 103. OCTALFA
  • 104. OPKO Biologics
  • 105. Oramed Pharmaceuticals
  • 106. Oxford Capital Partners
  • 107. Oxford Finance LLC
  • 108. Oxford Technology Venture Capital Trusts
  • 109. Palatin Technologies Inc.
  • 110. Peptor
  • 111. Peptron
  • 112. Pfenex
  • 113. Pfizer
  • 114. PhaseBio Pharmaceuticals
  • 115. Phoundry Pharmaceuticals
  • 116. PolyPeptide Laboratories (PPL)
  • 117. Proxima Concepts
  • 118. QS Pharma
  • 119 Quaker Partners
  • 120. Quilvest
  • 121. Quintiles
  • 122. RA Capital
  • 123. Radius Health
  • 124. Rani Therapeutics
  • 125. Rebel Pharmaceuticals
  • 126. RedCell
  • 127. Rhythm Pharmaceuticals
  • 128. Roche
  • 129. Rock Springs Capital
  • 130. Sanofi
  • 131. Servier
  • 132. Sham
  • 133. Shire
  • 134. Sofinnova Ventures
  • 135. SomPharmaceuticals
  • 136. Square 1 Bank
  • 137. Stealth BioTherapeutics
  • 138. Strongbridge Biopharma
  • 139. SurModics
  • 140. Tarix Pharmaceuticals
  • 141. Tarsa Therapeutics
  • 142. Teijin Pharma
  • 143. The Baupost Group
  • 144. Theratechnologies
  • 145. Thierry Abribat
  • 146. Transition Therapeutics
  • 147. TVM Capital
  • 148. Unigene Laboratories
  • 149. University of Alabama, Birmingham Research Foundation
  • 150. University of Geneva
  • 151. University of Nebraska-Lincoln
  • 152. University of Turin
  • 153. Uppsala University Hospital
  • 154. Upsher Smith Laboratories
  • 155. Vallaurix
  • 156. Venrock
  • 157. Versartis
  • 158. Vetter Pharma Fertigung & Co
  • 159. Weizmann Institute of Science
  • 160. Yeda Research and Development Company
  • 161. Ypsomed Group
  • 162. Zealand Pharma
  • 163. Zosano Pharma
Back to Top